• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伏格特-小柳-原田病:41例患者的回顾性多中心研究

Vogt-Koyanagi-Harada disease: a retrospective and multicentric study of 41 patients.

作者信息

Diallo K, Revuz S, Clavel-Refregiers G, Sené T, Titah C, Gerfaud-Valentin M, Seve P, Jaussaud R

机构信息

Department of Internal Medicine, Nancy University Hospital, Nancy, France.

Department of Internal Medicine, Metz Private Hospital, Metz, France.

出版信息

BMC Ophthalmol. 2020 Oct 7;20(1):395. doi: 10.1186/s12886-020-01656-x.

DOI:10.1186/s12886-020-01656-x
PMID:33028239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7539440/
Abstract

BACKGROUND

East and South East Asian subjects as well as Amerindians and Hispanic subjects are predominantly affected by Vogt-Koyanagi-Harada disease. In Europe, only few studies have described the clinical features and treatment of this disease, especially in France.

METHODS

This retrospective case series was based on data collected from patients with a VKH disease diagnosed from January 2000 to March 2017, provided by three French Tertiary Centers.

RESULTS

Forty-one patients (16 men and 25 women) were diagnosed: average age at diagnosis was 38.7 years. Patients were mainly from Maghreb (58%), but ethnic origins were multiple. Pleiocytosis was observed in 19 cases (63%) and 17 out of 41 patients showed audio vestibular signs (41%), and 11 showed skin signs (27%). Thirty-four were treated with corticosteroids (83%), 11 with an immunosuppressant treatment (27%) and 5 with biological therapy drugs (13%). Relapse was observed in 41% patients, even though final average visual acuity had improved. We did not find any significant clinical difference in the population from Maghreb compared to other populations, but for age and sex trends, since there was a majority of younger women.

CONCLUSION

We report here the second largest French cohort reported to date to our knowledge. The multiethnicity in our study suggests that VKH disease should be evoked whatever patients' ethnicity.

摘要

背景

东亚和东南亚人群以及美洲印第安人和西班牙裔人群主要受伏格特-小柳-原田病影响。在欧洲,只有少数研究描述了这种疾病的临床特征和治疗方法,尤其是在法国。

方法

本回顾性病例系列基于从2000年1月至2017年3月诊断为伏格特-小柳-原田病的患者收集的数据,这些数据由法国三个三级医疗中心提供。

结果

共诊断出41例患者(16名男性和25名女性):诊断时的平均年龄为38.7岁。患者主要来自马格里布地区(58%),但种族来源多样。19例(63%)出现脑脊液细胞增多,41例患者中有17例出现听觉前庭症状(41%),11例出现皮肤症状(27%)。34例接受了皮质类固醇治疗(83%),11例接受了免疫抑制治疗(27%),5例接受了生物治疗药物(13%)。41%的患者出现复发,尽管最终平均视力有所改善。与其他人群相比,我们未发现马格里布人群有任何显著的临床差异,但在年龄和性别趋势方面存在差异,因为年轻女性占多数。

结论

据我们所知,我们在此报告了法国迄今为止第二大的队列研究。我们研究中的多民族性表明,无论患者种族如何,都应考虑伏格特-小柳-原田病。

相似文献

1
Vogt-Koyanagi-Harada disease: a retrospective and multicentric study of 41 patients.伏格特-小柳-原田病:41例患者的回顾性多中心研究
BMC Ophthalmol. 2020 Oct 7;20(1):395. doi: 10.1186/s12886-020-01656-x.
2
Prevalence, clinical characteristics, and causes of vision loss in children with Vogt-Koyanagi-Harada disease in South India.印度南部 Vogt-Koyanagi-Harada 病患儿的患病率、临床特征和致盲原因。
Retina. 2010 Jul-Aug;30(7):1113-21. doi: 10.1097/IAE.0b013e3181c96a87.
3
The spectrum of Vogt-Koyanagi-Harada disease in Tunisia, North Africa.北非突尼斯的伏格特-小柳-原田病谱系
Int Ophthalmol. 2007 Apr-Jun;27(2-3):125-30. doi: 10.1007/s10792-006-9013-x. Epub 2007 Jan 4.
4
Vogt-Koyanagi-Harada Syndrome in Brazilian Children.巴西儿童的 Vogt-Koyanagi-Harada 综合征。
Ocul Immunol Inflamm. 2020 Apr 2;28(3):402-408. doi: 10.1080/09273948.2019.1588982. Epub 2019 May 23.
5
Vogt-Koyanagi-Harada disease in Spain.西班牙的伏格特-小柳-原田病。
Eur J Ophthalmol. 2022 May;32(3):1547-1554. doi: 10.1177/11206721211033477. Epub 2021 Jul 16.
6
Vogt-koyanagi-harada syndrome.伏格特-小柳-原田综合征
Curr Eye Res. 2008 Jul;33(7):517-23. doi: 10.1080/02713680802233968.
7
Vogt-Koyanagi-Harada Syndrome in a Canadian First Nations Population.加拿大原住民群体中的 Vogt-Koyanagi-Harada 综合征。
Ocul Immunol Inflamm. 2022 May 19;30(4):894-900. doi: 10.1080/09273948.2020.1849737. Epub 2021 Feb 23.
8
Vogt-Koyanagi-Harada disease in Thai patients.泰国患者的伏格特-小柳-原田病
J Med Assoc Thai. 2005 Nov;88 Suppl 9:S26-30.
9
The spectrum of Vogt-Koyanagi-Harada disease in Turkey: VKH in Turkey.土耳其伏格特-小柳-原田病的谱系:土耳其的伏格特-小柳-原田病
Int Ophthalmol. 2007 Apr-Jun;27(2-3):117-23. doi: 10.1007/s10792-006-9001-1. Epub 2006 Sep 7.
10
Vogt-Koyanagi-Harada Syndrome in a Group of Patients in Two Ophthalmology Referral Centers in Bogotá, Colombia.哥伦比亚波哥大两家眼科转诊中心的一组患者中的 Vogt-Koyanagi-Harada 综合征。
Ocul Immunol Inflamm. 2018;26(7):1123-1127. doi: 10.1080/09273948.2017.1341536. Epub 2017 Sep 14.

引用本文的文献

1
Comparative study of efficacy and safety of pulse versus half-pulse steroid therapy for Vogt-Koyanagi-Harada Disease.脉冲式与半脉冲式类固醇疗法治疗Vogt-小柳-原田病的疗效与安全性比较研究
Jpn J Ophthalmol. 2025 May 26. doi: 10.1007/s10384-025-01213-3.
2
Managing Vogt-Koyanagi-Harada disease during pregnancy with steroid pulse therapy: A case report.孕期采用类固醇脉冲疗法治疗Vogt-小柳原田病:一例报告
World J Clin Cases. 2024 Nov 6;12(31):6493-6499. doi: 10.12998/wjcc.v12.i31.6493.
3
Vogt-Koyanagi-Harada-Like Uveitis Secondary to Pembrolizumab in Metastatic Gastric Cancer: A Case Report and Review of the Literature.

本文引用的文献

1
"Revised diagnostic criteria" for Vogt-Koyanagi-Harada disease fail to improve disease management.Vogt-小柳-原田病的“修订诊断标准”未能改善疾病管理。
J Curr Ophthalmol. 2018 Dec 13;31(1):1-7. doi: 10.1016/j.joco.2018.10.011. eCollection 2019 Mar.
2
Corticotherapy vs. Corticotherapy Plus Immunosuppressive Therapy in Acute Vogt-Koyanagi-Harada Disease.急性Vogt-小柳-原田病中皮质类固醇疗法与皮质类固醇疗法联合免疫抑制疗法的比较
Arch Soc Esp Oftalmol (Engl Ed). 2018 May;93(5):225-230. doi: 10.1016/j.oftal.2017.09.010. Epub 2017 Dec 16.
3
Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.
帕博利珠单抗继发于转移性胃癌的类伏格特-小柳-原田葡萄膜炎:一例报告及文献复习
Case Rep Oncol. 2024 Sep 25;17(1):1071-1086. doi: 10.1159/000541133. eCollection 2024 Jan-Dec.
4
HIGH LONG-TERM DRUG-FREE REMISSION RATE FOR ACUTE VOGT-KOYANAGI-HARADA DISEASE WITH AN APPROPRIATE IMMUNOSUPPRESSIVE REGIMEN.适当的免疫抑制治疗方案可实现急性 Vogt-Koyanagi-Harada 病的长期无药物缓解。
Retina. 2023 Sep 1;43(9):1496-1505. doi: 10.1097/IAE.0000000000003837.
5
Uveitis in Children and Adolescents.儿童和青少年的葡萄膜炎。
Rheum Dis Clin North Am. 2021 Nov;47(4):619-641. doi: 10.1016/j.rdc.2021.07.005. Epub 2021 Aug 27.
皮质类固醇相关性不良事件系统地随着非感染性中、后或全葡萄膜炎的皮质类固醇剂量增加而增加:来自 VISUAL-1 和 VISUAL-2 试验的事后分析。
Ophthalmology. 2017 Dec;124(12):1799-1807. doi: 10.1016/j.ophtha.2017.06.017. Epub 2017 Jul 6.
4
Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.在VISUAL - 1和VISUAL - 2试验中,阿达木单抗对非感染性中间葡萄膜炎、后葡萄膜炎和全葡萄膜炎患者视觉功能的影响。
JAMA Ophthalmol. 2017 Jun 1;135(6):511-518. doi: 10.1001/jamaophthalmol.2017.0603.
5
Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.霉酚酸酯联合全身用糖皮质激素可预防与Vogt-小柳-原田病相关的初发性急性葡萄膜炎进展为慢性复发性炎症和“晚霞眼底”的形成。
Acta Ophthalmol. 2017 Feb;95(1):85-90. doi: 10.1111/aos.13189. Epub 2016 Aug 18.
6
Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes.伏格特-小柳-原田病:一种罕见的针对黑素细胞抗原的自身免疫性疾病的综述
Orphanet J Rare Dis. 2016 Mar 24;11:29. doi: 10.1186/s13023-016-0412-4.
7
Incidence and Management of Glaucoma in Vogt Koyanagi Harada Disease.小柳原田病中青光眼的发病率及管理
J Glaucoma. 2016 Aug;25(8):674-80. doi: 10.1097/IJG.0000000000000400.
8
Autoimmune uveitis: clinical, pathogenetic, and therapeutic features.自身免疫性葡萄膜炎:临床、发病机制及治疗特点
Clin Exp Med. 2016 May;16(2):125-36. doi: 10.1007/s10238-015-0345-6. Epub 2015 Mar 28.
9
High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada disease treated with early high-dose corticosteroids.早期大剂量皮质类固醇治疗 Vogt-Koyanagi-Harada 病患者的临床复发率高。
Graefes Arch Clin Exp Ophthalmol. 2015 May;253(5):785-90. doi: 10.1007/s00417-014-2904-z. Epub 2015 Jan 16.
10
Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease.在一部分小柳原田病患者中,早期免疫调节治疗与更好的视力预后相关。
Acta Ophthalmol. 2015 Sep;93(6):e475-80. doi: 10.1111/aos.12648. Epub 2015 Jan 7.